RespireRx

From Wikipedia, the free encyclopedia
  (Redirected from RespireRx Pharmaceuticals)
Jump to navigation Jump to search

RespireRx Pharmaceuticals Inc. (formerly Cortex Pharmaceuticals, Inc.) (OTCQBRSPI) is a pharmaceutical company based in Glen Rock, New Jersey specializing in positive allosteric modulators of the AMPA receptor known as Ampakines.

History[edit]

February 2005 – Cortex received U.S. Food and Drug Administration approval to begin Phase II clinical trials for CX717 for use as a treatment for Alzheimer’s, ADHD and Sleep disorders.[1]
2006 – The FDA halted clinical trials for CX717 because they feared the drug was toxic. They later allowed testing to continue but at doses too low to have any effect.[2]
July 2007 – The FDA gave Cortex permission to continue with clinical trials for CX717, as a treatment for Alzheimer's disease.
September 2007 – Cortex filed with the FDA to test CX717 as a treatment for ADHD.
October 2007 – Dr. Pierre Tran became Chief Medical Officer at Cortex after the FDA refused to let the company proceed with Phase II clinical trials for CX717 as a treatment for ADHD.[3]
March 2008 – German regulators approved clinical studies for using CX717 to prevent breathing problems caused by opiate pain-killers. May 2008 – President and CEO Dr. Roger Stoll announced that he was resigning and would be replaced by Mark Varney.[4]

On June 13, 2018, RespireRx Pharmaceuticals Inc entered into a letter of intent with Noramco Inc, a producer of controlled substances bulk APIs for the pharmaceutical industry, pursuant to which the parties have entered into a 90-day period during which they will negotiate a definitive agreement regarding the RespireRx’s development of dronabinol, a synthetic cannabinoid, also known as Δ9-tetrahydrocannabinol or Δ9-THC.[5]   

References[edit]

  1. ^ News: Today's Orange County business briefs - OCRegister.com
  2. ^ Money: Innovative biomed companies woo investors - OCRegister.com
  3. ^ Cortex Pharmaceuticals - OC Business News - OCRegister.com Archived 2008-05-07 at the Wayback Machine
  4. ^ Cortex Pharmaceuticals - Biomedical Innovation with Colin Stewart - OCRegister.com Archived 2008-01-04 at the Wayback Machine
  5. ^ "RespireRx Takes Step to Advance Dronabinol Obstructive Sleep Apnea Program with Letter of Intent for Co-Development and Supply Agreement". Sleep Review. Retrieved 2019-05-21.

External links[edit]